Insider sales are de minimis and largely under a 10b5-1 plan. No bearish signal; monitor next 10-Q for any change in fundamentals.
LGND drugs
LGND drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $314.15entry
- T+1 · 7d ago +0.00%α +0.37% · $314.16
- T+5 · 18h ago −3.96%α −2.27% · $301.71
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Two insiders at Ligand Pharmaceuticals sold shares in the week following the company's Q3 earnings beat and raised guidance. The CLO sold under a 10b5-1 plan, while a director sold without one. Total open-market sales of $155K are trivial relative to the $6.3B market cap (0.0025%), making this a routine liquidity event with no material signal.
Key Financial Metrics
Key Facts
- Two insiders sold shares: CLO Andrew Reardon (10b5-1 plan) and director Aryeh Jason (no plan)
- Total open-market sales: $155K (0.0025% of $6.3B market cap)
- Sales occurred 4-6 days after Q3 earnings beat and raised guidance
- CLO Reardon also exercised 5,000 derivative shares at $0 and $52.27 on Nov 2 (non-cash events)
- Director Jason sold 700 shares ($224K) on Nov 2 and 282 shares ($90K) on Nov 4
Financial Impact
Total open-market sales of $155K, immaterial relative to $6.3B market cap
Risk Factors
- Director Jason's sale without a 10b5-1 plan could indicate personal liquidity needs, not a negative view
- No material risk identified from this cluster
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-LGND-1794004938540 |
Track record
29 reports on LGND
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +38.85% at T+60 after the Apr 14, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $305.74 Now $301.71 −1.32% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $306.47 Now $301.71 −1.55% settles Feb 12
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $308.79 Now $301.71 −2.29% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $316.27 Now $301.71 −4.60% settles Feb 10
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $316.83 Now $301.71 −4.77% settles Feb 9
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $314.16 Now $301.71 −3.96% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Viewing Entry $314.15 Now $301.71 −3.96% settles Feb 5
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $299.00 Now $301.71 +0.91% settles Feb 3
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers